Sprycel 70mg Tablet
Prescription Required
Manufactured By
bms india
Pack of
60 tablet
Salt Composition
Dasatinib
Storage
Keep in cold place
Delivering To: —
All Substitutes
Overview
The Sprycel 70mg Tablet is used to treat chronic myeloid leukemia, or blood cancer. Patients who are unable to take other leukemia medications due to adverse effects or whose disease cannot be treated with them are treated with it. It is a member of the class of drugs called protein-tyrosine kinase inhibitors. This medication functions by preventing the abnormal protein that instructs cancer cells to proliferate from doing its job. It is crucial that you take this medication exactly as directed by your physician. While taking this medication, blood cell counts must be closely monitored.
Indication
Blood Cancer
Uses
Blood cancer (Chronic myeloid leukaemia)
Side Effects
Sprycel may cause some common side effects. Before starting treatment, discuss the risks and benefits of Sprycel tablets, as well as your medical history, with your doctor.
Bleeding gums
Constipation
Coughing up blood
Body pain
Dizziness
Weight gain
Irregular heartbeat
Sore throat
Headache
Nasal congestion
Anemia
Fatigue
Nausea
Infection
Low blood platelets
Dosage and Administration
Take Sprycel 70mg Tablet as prescribed by your doctor. Do not stop or skip your regular dosing schedule. In case of an overdose of Sprycel tablets, the doctor will provide emergency medical treatment.
Mechanism of action
Acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) cell lines that overexpressed BCR-ABL were reduced in their proliferation by dasatinib. Dasatinib successfully overcame imatinib resistance caused by mutations in the BCR-ABL kinase domain, activation of alternative signaling pathways involving the SRC family kinases (LYN, HCK), and overexpression of multi-drug resistance genes under the assay conditions. The effects of this medication can be seen one to six hours after oral consumption.
Safety Advice
Alcohol
unsafe
It is advisable not to consume alcohol while taking this medicine.
Pregnancy
consult your doctor
Do not take Sprycel 70mg Tablet without consulting the doctor, in case of pregnancy.
Breast Feeding
consult your doctor
Without a doctor's consultation, do not take this medicine if you're breastfeeding.
Driving
danger
It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.
Kidney
caution
Do not consume Sprycel 70mg Tablet without a doctor's consultation in case of kidney problems.
Liver
caution
Share your medical history with the doctor in case of liver disease before taking this medicine.
Missed Doses
It is advisable not to miss a dose. If you miss a scheduled dose of Sprycel tablets, contact your doctor immediately.
FAQs
This medicine is used for the treatment of blood cancer, and it helps to prevent the growth of cancer cells.
Some common side effects of this medicine are bleeding, constipation, weight gain, sore throat, dizziness, fatigue, anemia, etc.
This medicine works by blocking the action of the abnormal protein that signals cancer cells to multiply.
It is advised not to drive after taking Sprycel 70mg Tablet. This medicine may affect your vision and your ability to concentrate.
Follow your doctor’s advice about any restrictions on food and other activities.
Trusted Medicines, Delivered Worldwide
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We Currently Ship To:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Reference
D., Cheng, H., Guo, J., Jiang, R.,Zhang, Y., Wan, C., Qin, J., Yuan, G., Chen, S., Yang, Z., Hu, J., Zhang, Y., & Li, W. (2023). 1-year results of dasatinib 70 mg/day versus 100 mg/day in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML‑CP): A prospective randomized controlled study. Hemasphere, 7(Suppl), e8560105. https://doi.org/10.1097/01.HS9.0000969568.85601.05
Silver, R. T., et al. (2006). Dasatinib (SPRYCEL®) 70 mg twice daily versus other dosing schedules in patients with imatinib-resistant or intolerant CML‑CP: Results from CA180‑034 (START‑C). Blood, 108(11), 166. https://doi.org/10.1182/blood.V108.11.166.166.
Kantarjian, H. M., et al. (2023). Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed CML‑CP: 5‑year follow-up results. https://pubmed.ncbi.nlm.nih.gov/37308342/
Satadeve, P. (2025). Comparison of molecular response and safety of lower dose (70 mg) versus standard dose (100 mg) of generic dasatinib in newly diagnosed CML-CP: A randomized controlled study from India. Paper presented at the EHA 2025 Congress. https://www.cml-foundation.org/86-news-icmlf/2333-eha2025-daily-updates-3.html
Shah, N. P., Kantarjian, H., Kim, D.-W., Rea, D., Dorlhiac-Llacer, P., Milone, J. H., ... & Baccarani, M. (2008). Intermittent target inhibition with dasatinib 100 mg once Daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology, 26(19), 3204–3212. https://doi.org/10.1200/JCO.2007.14.8676
Related Products
MARKETER DETAILS
bms india
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.